Pharma BD Deal Intelligence

UCB S.A. / Candid Therapeutics, Inc.

2026 · Acquisition/Merger · $2.2B · Pending

UCB signed a definitive agreement to acquire privately held Candid Therapeutics for up to $2.2B ($2.0B upfront + $200M milestones), gaining lead asset cizutamig, a BCMAxCD3 bispecific T-cell engager in clinical development across more than 10 autoimmune indications. The deal builds UCB's immunology pipeline in B-cell-driven autoimmune diseases. Closing is anticipated in late Q2/early Q3 2026 subject to antitrust clearance.

Key facts

• Announced May 03, 2026
• Deal value $2.2B
• Deal type Acquisition/Merger
• Therapeutic area Autoimmune and inflammatory diseases (myasthenia gravis, lupus, systemic sclerosis, IgA nephropathy, others)
• Indications Autoimmune and inflammatory diseases (myasthenia gravis, lupus, systemic sclerosis, IgA nephropathy, others)
• Key assets cizutamig (BCMAxCD3 bispecific T-cell engager)
• Mechanism BCMA x CD3 bispecific T-cell engager for plasma-cell/B-cell depletion and immune reset

← Browse all deals  ·  How we score deals